Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ME-344 in Early HER2-negative Breast Cancer With Antiangiogenic-induced Mitochondrial Metabolism: a Phase 0 Trial

NCT02806817 is registered in ClinicalTrials.gov with Centro Nacional de Investigaciones Oncologicas CARLOS III as lead sponsor.

NCT NCT02806817
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02806817 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ME-344 in Early HER2-negative Breast Cancer With Antiangiogenic-induced Mitochondrial Metabolism: a Phase 0 Trial
Lead sponsor
Centro Nacional de Investigaciones Oncologicas CARLOS III
Phase
Phase 1
Overall status
Completed
Start date
July 31, 2016
Completion date
November 30, 2018
Enrollment
40 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, early-stage breast carcinoma, human epidermal growth factor 2 negative carcinoma of breast